Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience (NASDAQ:LEXX), a global drug delivery platform innovator, has announced a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,666,667 shares of common stock at $1.50 per share.
Additionally, in a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to 2,666,667 shares with an exercise price of $1.37 per share. The warrants will be immediately exercisable and expire in five years. H.C. Wainwright & Co. serves as the exclusive placement agent, with the offering expected to close around September 29, 2025.
Lexaria Bioscience (Nasdaq:LEXX) has announced positive results from its fluorescently tagged semaglutide (FTS) rodent biodistribution study, demonstrating that its DehydraTECH technology enhances brain delivery of the GLP-1 drug semaglutide.
The study revealed that DehydraTECH-FTS showed higher brain biodistribution compared to Rybelsus® equivalent composition, with the 5mg DehydraTECH-FTS achieving higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent. The enhanced brain delivery could potentially improve both safety and efficacy of GLP-1 drugs, particularly in areas related to appetite suppression and nausea reduction.
These findings suggest that Lexaria's technology may enable unique delivery enhancements in brain tissue, potentially supporting improved pharmacodynamic performance of GLP-1 drugs.
Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference from September 8-10th, 2025.
CEO Richard Christopher will deliver a company presentation, which will be available for remote viewing starting September 5th at 7:00 AM EST. The management team will also be available for one-on-one meetings with investors throughout the conference.
Lexaria Bioscience (NASDAQ:LEXX) has achieved the Last Patient Last Visit (LPLV) milestone in its Phase 1b GLP-1 study in Australia. The study, designated as GLP-1-H24-4, is currently in the laboratory analysis phase where thousands of samples are being processed and analyzed.
The company previously reported positive 8-week interim results showing encouraging safety and tolerability data compared to the Rybelsus® control arm, particularly noting reduced gastrointestinal adverse events. The final report is expected in late 2025.
Lexaria Bioscience (NASDAQ:LEXX) provides an update on the expanding GLP-1 and obesity drug market, highlighting its DehydraTECH technology's potential role. The market is expected to exceed $150 billion by 2030, with 39 new GLP-1 drugs in development from 34 companies.
The company's DehydraTECH platform has demonstrated significant reductions in gastrointestinal adverse events across major GLP-1 drugs, showing improvements ranging from 31% to 100% in various studies. The update also details recent major industry deals, including Novo Nordisk's $2.2 billion collaboration with Septerna, Roche's $5.3 billion rights acquisition from Zealand Pharma, and Regeneron's $1.93 billion licensing deal with Hansoh Pharmaceutical.
Lexaria Bioscience (NASDAQ:LEXX) has reported positive interim 8-week results from its Phase 1b GLP-1-H24-4 study comparing DehydraTECH-enhanced semaglutide and tirzepatide to Rybelsus®. The study revealed that DehydraTECH-semaglutide reduced overall adverse events by 36.5% and gastrointestinal side effects by 43.5% compared to Rybelsus®.
Key findings show that only 79.2% of DehydraTECH-semaglutide patients experienced adverse events, compared to 100% in the Rybelsus® group. For weight loss, DehydraTECH-semaglutide showed a reduction of 1.23% after 8 weeks, while HbA1c levels decreased by 0.14%. The study is expected to complete with final results by the end of 2025.
Lexaria Bioscience (NASDAQ:LEXX) positions its DehydraTECH technology as a potential solution for the GLP-1 industry's biggest challenge: adverse effects. The GLP-1 market is experiencing remarkable growth, with projected revenues increasing from $53.5 billion in 2024 to $70.1 billion in 2025, and expected to reach $156 billion by 2030.
However, 47-64% of GLP-1 users discontinue treatment within 1-2 years, primarily due to gastrointestinal side effects. Notably, 75.7% of patients experience gastrointestinal adverse events with leading GLP-1 drugs. Lexaria's DehydraTECH technology has demonstrated in human clinical testing its ability to reduce side effects in the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide.
The company is currently collaborating with a pharmaceutical partner ("PharmaCO") under a material transfer agreement announced in September 2024 to evaluate DehydraTECH compositions.